Curatis enters SIX Swiss Exchange following the acquisition of Kinarus

Early this year, Curatis announced the reverse merger with Kinarus, a publicly listed specialty pharmaceutical company with a distribution and drug development business, to save it from bankruptcy. The business combination of the two companies has now been completed and new changes have been enforced. Kinarus Therapeutics Holding AG has been renamed to Curatis Holding AG while Curatis is now listed on the Swiss Exchange under the name of Curatis Group (CURN.SW) with a domicile in Liestal, Basel-Landschaft. A total of CHF 4.36m in cash was raised in Q1 2024 in connection with the business combination.

Marian Borovsky, Chairman of Curatis Holding AG says, “We are very excited about this Business Combination as it allows Curatis AG to continue its successful business activities as part of a publicly listed group and adds Kinarus’ compound platform KIN001 to our promising development portfolio (...). ”With Curatis now being part of a publicly listed group and the expected increase in public visibility and credibility, the company aims to grow its speciality pharmaceuticals distribution business by expanding its product offering in Switzerland as well as geographically expanding its distribution business to large European markets such as Germany, France, the U.K., and Italy.Founded in 2002, Curatis is focused on the acquisition, development and commercialisation of innovative medicines for the prevention, diagnosis and treatment of rare diseases - often referred to as orphan diseases - and special care diseases. It also operates a distribution business with a sizeable and historically profitable portfolio of interesting, marketed orphan and speciality products in Switzerland and has a pipeline of four promising projects in advanced and late clinical development.